Genetics and fatty liver disease in Caribbean and Indian Ocean populations
Part of Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-alcoholic fatty liver disease (MASLD) with steatosis (fat in the liver) plus overweight, obesity, type 2 diabetes, or metabolic syndrome.
- You are seen at one of the study hospitals in Guadeloupe, French Guiana, or Réunion Island.
- You are covered by a social security plan and can give written consent.
- You do not have other liver diseases (like hepatitis, alcoholic liver disease, or genetic disorders).
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
This study looks at how a gene variant (PNPLA3) relates to gut bacteria in Hispanic patients with fatty liver disease (MASLD) in Puerto Rico. It aims to understand the connection between your genes, your gut health, and your liver condition.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
Hear when a new MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.